Summary

The global oligonucleotide CDMO market is projected to reach USD 6.73 billion in 2029 from USD 2.51 billion in 2024, with a CAGR of 21.8% during the forecast period. Key factors driving market growth include increasing focus on the launch of novel oligo-based drugs and growing outsourcing to CDMOs. Oligonucleotides, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, are being focused on due to the specificity and targeted action offered by these drugs. This has led to an increase in development activity followed by FDA approvals. For instance, in April 2023, Qalsody (tofersen) was approved by the US FDA for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Additionally, expertise and lower costs incurred while outsourcing clinical development and manufacturing (clinical and commercial) further support the growth of this market.
“The contract manufacturing segment accounted for the largest share in the oligonucleotide CDMO market, by service type, in 2023”
In 2023, contract manufacturing segment accounted for the largest share of the oligonucleotide CDMO market. Factors such as expertise offered by CDMOs leading to the reduction in production timelines and improving production scalability, supported by an increase in the demand for oligonucleotide therapeutics are supporting the growth of this segment. Additionally, regulatory expertise offered by CDMOs further reduces time-to-market and operational risks is another factor driving the outsourcing of manufacturing to CDMOs.
“The pharmaceutical and biotechnology companies end-user segment registered the highest growth rate and largest market share in the oligonucleotide CDMO market, by end user, during the forecast period”
Pharmaceutical and biotechnology companies are major end user segments of the oligonucleotide CDMO market. The increasing clinical and commercial demand for oligo-based therapies drives pharma and biotech companies to engage CDMOs for production. Oligonucleotide synthesis is complex and requires specialized expertise, high-end technologies, and regulatory compliance. CDMOs have established infrastructure and systems in place for offering to these companies. Thus, pharmaceutical and biotechnology companies largely rely on CDMOs, mainly for manufacturing, fill-finish, and other services.

“Asia Pacific: The fastest growing region in the oligonucleotide CDMO market”
Asia Pacific region, with countries like China, India, Japan, and South Korea are experiencing rapid growth in their biopharmaceutical industries, with increased focus on innovative therapies such as oligonucleotide-based drugs. Additionally, the Asia Pacific region offers significant cost advantages for CDMO services due to lower labor, production, and operational costs. This is attracting global players to outsource manufacturing activities from the Asia Pacific region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Supply Side - 65% and Demand Side – 35%
• By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa - 5%
List of Companies Profiled in the Report:
• Bachem (Switzerland)
• Thermo Fisher Scientific Inc. (US)
• Agilent Technologies, Inc. (US)
• Maravai Lifesciences (US)
• GenScript (US)
• Wuxi Apptec (China)
• Eurofins Scientific (Luxembourg)
• Lonza (Switzerland)
• Danaher Corporation (US)
• Syngene International Limited (US)
• EUROAPI (France)
• Ajinomoto Co., Inc. (Japan)
• ST Pharm (South Korea)
• Kaneka Corporation (Japan)
• Aurigene Pharmaceutical Services Ltd. (India)
• PolyPeptide Group (Switzerland)
• Biospring (Germany)
• Oligo factory (US)
• Corden Pharma (Switzerland)
• LGC Biosearch Technologies (UK)
• Bio-Synthesis Inc (US)
• Microsynth (Switzerland)
• Synoligo Biotechnologies, Inc. (US)
• Hongene Biotech Corporation (China)
• Sylentis, S.A. (Spain)
• Creative Biogene. (US)
Research Coverage:
This report provides a detailed picture of the global oligonucleotide CDMO Market. It aims to estimate the size and future growth potential of the market across different segments such as service type, stage, type, application, end users and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide CDMO market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, mergers and acquisitions, and recent developments associated with the protein expression market. Competitive analysis of upcoming startups in the oligonucleotide CDMO market ecosystem is covered in this report.
Reasons to buy this report :
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall oligonucleotide CDMO market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:
• Analysis of key drivers (Growing focus on development and commercialization of oligo-based therapeutics), restraints (Complexities associated with oligonucleotide manufacturing ), opportunities (Increasing use of oligos for CRISPR/Cas 9 application), and challenges (Lack of sustainable and eco-friendly supply chain) influencing the growth of the oligonucleotide CDMO market.
• Innovation: Detailed insights on upcoming technologies, research & development activities, in the oligonucleotide CDMO market
• Market Development: Comprehensive information about lucrative markets – the report analyses the oligonucleotide CDMO market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the oligonucleotide CDMO market like- Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), EUROAPI (France), ST Pharm (South Korea), Wuxi Apptec (China), Maravai Lifesciences (US), and Biospring (Germany) among others

ページTOPに戻る

Table of Contents

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED & REGIONS CONSIDERED 28
1.3.2 INCLUSIONS & EXCLUSIONS 29
1.3.3 YEARS CONSIDERED 29
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.1.1 SECONDARY DATA 32
2.1.2 PRIMARY DATA 33
2.2 MARKET ESTIMATION METHODOLOGY 34
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 37
2.2.2 TOP-DOWN APPROACH 37
2.3 MARKET GROWTH RATE PROJECTIONS 38
2.4 DATA TRIANGULATION 40
2.5 RESEARCH ASSUMPTIONS 41
2.6 RESEARCH LIMITATIONS 41
2.7 RISK ANALYSIS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 47
4.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW 47
4.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE & COUNTRY (2023) 48
4.3 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024 VS 2029 48
4.4 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024 VS 2029 49
4.5 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY END USER, 2023 49
4.6 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
 
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 52
5.2.1.1 Growing focus on development and commercialization of oligo-based therapeutics 52
5.2.1.2 Advantages of contract development and manufacturing 54
5.2.1.3 Increasing focus on precision/personalized medicine 54
5.2.1.4 Technological advancements 54
5.2.2 RESTRAINTS 55
5.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing 55
5.2.3 OPPORTUNITIES 56
5.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications 56
5.2.4 CHALLENGES 56
5.2.4.1 Lack of sustainable and eco-friendly supply chain 56
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 57
5.4 SUPPLY CHAIN ANALYSIS 57
5.5 VALUE CHAIN ANALYSIS 58
5.6 ECOSYSTEM ANALYSIS 60
5.6.1 ROLE IN ECOSYSTEM 60
5.7 TECHNOLOGY ANALYSIS 62
5.7.1 KEY TECHNOLOGIES 62
5.7.1.1 Process technologies 62
5.7.1.1.1 Solid-phase synthesis 62
5.7.1.1.2 Liquid-phase synthesis 62
5.7.1.1.3 Enzymatic oligo synthesis 63
5.7.2 COMPLEMENTARY TECHNOLOGIES 64
5.7.2.1 Purification, analysis, and quality control technologies 64
5.7.2.1.1 Chromatography 64
5.7.2.1.2 Mass spectrometry 64
5.7.2.2 Other technologies 64
5.7.2.2.1 Polymerase chain reaction (PCR) 64
5.7.2.2.2 Next-generation sequencing 65
5.7.3 ADJACENT TECHNOLOGIES 65
5.7.3.1 3D printing 65
5.8 PRICING ANALYSIS 66
5.8.1 INDICATIVE PRICE OF OLIGONUCLEOTIDE CDMO SERVICES, BY KEY PLAYER 66
5.8.2 AVERAGE SELLING PRICE, BY REGION (QUALITATIVE) 67
 
5.9 KEY CONFERENCES & EVENTS IN 2024–2025 67
5.10 REGULATORY LANDSCAPE 68
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
5.10.2 REGULATORY FRAMEWORK 71
5.11 PORTER’S FIVE FORCES ANALYSIS 72
5.11.1 DEGREE OF COMPETITION 73
5.11.2 BARGAINING POWER OF SUPPLIERS 73
5.11.3 BARGAINING POWER OF BUYERS 73
5.11.4 THREAT OF SUBSTITUTES 73
5.11.5 THREAT OF NEW ENTRANTS 73
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 74
5.12.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE CDMO SERVICES 74
5.13 KEY BUYING CRITERIA 75
5.14 INVESTMENT & FUNDING SCENARIO 76
5.15 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET 77
6 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE 79
6.1 INTRODUCTION 80
6.2 CONTRACT MANUFACTURING 80
6.2.1 COMMERCIAL STAGE 83
6.2.1.1 Flexible, scalable production facilities to propel market growth 83
6.2.2 CLINICAL STAGE 85
6.2.2.1 Growing demand for oligonucleotide-based therapeutics to drive market 85
6.3 CONTRACT DEVELOPMENT 88
6.3.1 GROWING FOCUS ON REDUCING MANUFACTURING RISKS TO SUPPORT MARKET GROWTH 88
6.4 OTHER SERVICES 90
7 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE 93
7.1 INTRODUCTION 94
7.2 ANTISENSE OLIGONUCLEOTIDES 94
7.2.1 SPECIFIC DEVELOPMENT & MANUFACTURING REQUIREMENTS WELL-SUPPORTED BY CDMOS TO DRIVE MARKET GROWTH 94
7.3 SMALL INTERFERING RNA 96
7.3.1 POTENTIAL IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH 96
7.4 OTHER OLIGONUCLEOTIDES 99
 
8 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION 102
8.1 INTRODUCTION 103
8.2 THERAPEUTIC APPLICATIONS 103
8.2.1 GROWING DEMAND FOR OLIGONUCLEOTIDE-BASED THERAPEUTICS TO DRIVE MARKET GROWTH 103
8.3 RESEARCH APPLICATIONS 105
8.3.1 USE OF OLIGOS IN SEQUENCING FOR ADVANCING DRUG DEVELOPMENT TO SUPPORT GROWTH 105
8.4 DIAGNOSTIC APPLICATIONS 108
8.4.1 GROWING APPLICATIONS IN MOLECULAR DIAGNOSTICS AND IVD TO PROPEL MARKET 108
9 OLIGONUCLEOTIDE CDMO MARKET, BY END USER 111
9.1 INTRODUCTION 112
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 112
9.2.1 INCREASED INVESTMENTS IN OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT MARKET GROWTH 112
9.3 DIAGNOSTIC COMPANIES 114
9.3.1 GROWTH OF PERSONALIZED DIAGNOSTICS TO PROPEL MARKET 114
9.4 OTHER END USERS 117
10 OLIGONUCLEOTIDE CDMO MARKET, BY REGION 120
10.1 INTRODUCTION 121
10.2 NORTH AMERICA 121
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 121
10.2.2 US 126
10.2.2.1 Rising approvals of oligonucleotide-based drugs to support market growth 126
10.2.3 CANADA 128
10.2.3.1 Government initiatives to drive market growth in Canada 128
10.3 EUROPE 130
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 130
10.3.2 GERMANY 133
10.3.2.1 Academic-industry collaborations to drive market 133
10.3.3 UK 136
10.3.3.1 Strategic investments in biomanufacturing to boost market growth 136
10.3.4 FRANCE 138
10.3.4.1 Focus on advanced biologics manufacturing to drive market 138
10.3.5 ITALY 140
10.3.5.1 Increasing focus on biotechnology innovation to boost market growth 140
10.3.6 SPAIN 142
10.3.6.1 Strategic investments in biotechnology to support market growth 142
10.3.7 REST OF EUROPE 144
10.4 ASIA PACIFIC 146
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 147
10.4.2 CHINA 151
10.4.2.1 Government-backed Initiatives and expansion of major companies to strengthen biotechnology sector in China 151
10.4.3 JAPAN 153
10.4.3.1 Increased investment in oligonucleotide research and manufacturing to boost market 153
10.4.4 INDIA 155
10.4.4.1 Rapidly expanding biopharma ecosystem to drive market 155
10.4.5 SOUTH KOREA 158
10.4.5.1 Robust government support to expand oligonucleotide CDMO sector 158
10.4.6 REST OF ASIA PACIFIC 160
10.5 LATIN AMERICA 162
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 163
10.5.2 BRAZIL 165
10.5.2.1 Strong research institutions and growing collaboration between academia and industry to support market growth 165
10.5.3 MEXICO 167
10.5.3.1 Rapidly advancing pharmaceutical and biotechnology sectors to fuel growth 167
10.5.4 REST OF LATIN AMERICA 169
10.6 MIDDLE EAST & AFRICA 171
10.6.1 RISING INVESTMENTS IN HEALTHCARE AND GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET 171
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 172
10.6.3 MACROECONOMIC OUTLOOK FOR AFRICA 172
11 COMPETITIVE LANDSCAPE 175
11.1 OVERVIEW 175
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 175
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET 176
11.3 REVENUE ANALYSIS, 2021–2023 177
11.4 MARKET SHARE ANALYSIS, 2023 178
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 180
11.5.1 STARS 180
11.5.2 EMERGING LEADERS 180
11.5.3 PERVASIVE PLAYERS 181
11.5.4 PARTICIPANTS 181
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 182
11.5.5.1 Company footprint 182
11.5.5.2 Region footprint 183
11.5.5.3 Service type footprint 184
11.5.5.4 Type footprint 185
11.5.5.5 Application footprint 186
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 187
11.6.1 PROGRESSIVE COMPANIES 187
11.6.2 RESPONSIVE COMPANIES 187
11.6.3 DYNAMIC COMPANIES 187
11.6.4 STARTING BLOCKS 187
11.6.5 COMPETITIVE BENCHMARKING 189
11.6.5.1 Detailed list of key startups/SMES 189
11.6.5.2 Competitive benchmarking of startups/SMEs 190
11.7 COMPANY VALUATION AND FINANCIAL METRICS 191
11.8 BRAND/SERVICE COMPARISON 192
11.9 COMPETITIVE SCENARIO 193
11.9.1 DEALS 193
11.9.2 EXPANSIONS 194
12 COMPANY PROFILES 196
12.1 KEY PLAYERS 196
12.1.1 BACHEM 196
12.1.1.1 Business overview 196
12.1.1.2 Services offered 197
12.1.1.3 Recent developments 198
12.1.1.3.1 Deals 198
12.1.1.4 MnM view 198
12.1.1.4.1 Key strengths 198
12.1.1.4.2 Strategic choices 198
12.1.1.4.3 Weaknesses and competitive threats 198
12.1.2 THERMO FISHER SCIENTIFIC INC. 199
12.1.2.1 Business overview 199
12.1.2.2 Services offered 200
12.1.2.3 Recent developments 201
12.1.2.3.1 Deals 201
12.1.2.3.2 Expansions 201
12.1.2.4 MnM view 201
12.1.2.4.1 Key strengths 201
12.1.2.4.2 Strategic choices 201
12.1.2.4.3 Weaknesses and competitive threats 202
 
12.1.3 AGILENT TECHNOLOGIES, INC. 203
12.1.3.1 Business overview 203
12.1.3.2 Services offered 204
12.1.3.3 Recent developments 205
12.1.3.3.1 Deals 205
12.1.3.3.2 Expansions 205
12.1.3.4 MnM view 206
12.1.3.4.1 Key strengths 206
12.1.3.4.2 Strategic choices 206
12.1.3.4.3 Weaknesses and competitive threats 206
12.1.4 WUXI APPTEC 207
12.1.4.1 Business overview 207
12.1.4.2 Services offered 208
12.1.4.3 Recent developments 209
12.1.4.3.1 Expansions 209
12.1.4.4 MnM view 209
12.1.4.4.1 Key strengths 209
12.1.4.4.2 Strategic choices made 209
12.1.4.4.3 Weaknesses and competitive threats 210
12.1.5 MARAVAI LIFESCIENCES 211
12.1.5.1 Business overview 211
12.1.5.2 Services offered 212
12.1.5.3 Recent developments 213
12.1.5.3.1 Deals 213
12.1.6 LONZA 214
12.1.6.1 Business overview 214
12.1.6.2 Services offered 215
12.1.6.3 Recent developments 216
12.1.6.3.1 Deals 216
12.1.6.3.2 Expansions 216
12.1.7 EUROFINS SCIENTIFIC 217
12.1.7.1 Business overview 217
12.1.7.2 Services offered 218
12.1.7.3 Recent developments 219
12.1.7.3.1 Deals 219
12.1.7.3.2 Expansions 219
12.1.8 DANAHER CORPORATION 220
12.1.8.1 Business overview 220
12.1.8.2 Services offered 222
12.1.8.3 Recent developments 222
12.1.8.3.1 Expansions 222
 
12.1.9 GENSCRIPT 223
12.1.9.1 Business overview 223
12.1.9.2 Services offered 224
12.1.9.3 Recent developments 225
12.1.9.3.1 Expansions 225
12.1.10 SYNGENE INTERNATIONAL LIMITED 226
12.1.10.1 Business overview 226
12.1.10.2 Services offered 227
12.1.10.3 Recent developments 227
12.1.10.3.1 Expansions 227
12.1.11 EUROAPI 228
12.1.11.1 Business overview 228
12.1.11.2 Services offered 229
12.1.11.3 Recent developments 230
12.1.11.3.1 Deals 230
12.1.11.3.2 Expansions 230
12.1.12 AJINOMOTO CO., INC. 231
12.1.12.1 Business overview 231
12.1.12.2 Services offered 232
12.1.13 ST PHARM 233
12.1.13.1 Business overview 233
12.1.13.2 Services offered 234
12.1.13.3 Recent developments 234
12.1.13.3.1 Expansions 234
12.1.13.3.2 Other developments 234
12.1.14 KANEKA CORPORATION 235
12.1.14.1 Business overview 235
12.1.14.2 Services offered 236
12.1.15 POLYPEPTIDE GROUP 237
12.1.15.1 Business overview 237
12.1.15.2 Services offered 238
12.1.15.3 Recent developments 239
12.1.15.3.1 Deals 239
12.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD. 240
12.1.16.1 Business overview 240
12.1.16.2 Services offered 240
12.1.17 BIOSPRING 241
12.1.17.1 Business overview 241
12.1.17.2 Services offered 241
12.1.17.3 Recent developments 242
12.1.17.3.1 Service approvals 242
12.1.17.3.2 Expansions 242
12.2 OTHER PLAYERS 243
12.2.1 OLIGO FACTORY 243
12.2.2 CORDEN PHARMA 243
12.2.3 LGC BIOSEARCH TECHNOLOGIES 244
12.2.4 BI0-SYNTHESIS, INC. 244
12.2.5 MICROSYNTH 245
12.2.6 SYNOLIGO BIOTECHNOLOGIES, INC. 245
12.2.7 HONGENE BIOTECH CORPORATION 246
12.2.8 SYLENTIS, S.A. 246
12.2.9 CREATIVE BIOGENE 247
13 APPENDIX 248
13.1 DISCUSSION GUIDE 248
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 251
13.3 CUSTOMIZATION OPTIONS 253
13.4 RELATED REPORTS 253
13.5 AUTHOR DETAILS 254